United States - English - NLM (National Library of Medicine)

macoven pharmaceuticals - desvenlafaxine (unii: ng99554anw) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine 50 mg - desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14)] . - hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation.  angioedema has been reported in patients treated with desvenlafaxine [see adverse reactions (6.1)] . - the use of maois intended to treat psychiatric disorders with desvenlafaxine extended-release tablets or within 7 days of stopping treatment with desvenlafaxine extended-release tablets is contraindicated because of an increased risk of serotonin syndrome. the use of desvenlafaxine extended-release tablets within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration  (2.8)   and  warnings and precautions  (5.2)]. -   starting desvenlafaxine extended-release tablets in a patient who is being treated with maois such as linezolid or intraveno

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - venlafaxine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - venlafaxine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - venlafaxine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - venlafaxine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - venlafaxine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - venlafaxine hydrochloride, quantity: 84.86 mg - capsule, modified release - excipient ingredients: hypromellose; magnesium stearate; sodium lauryl sulfate; ammonio methacrylate copolymer; basic butylated methacrylate copolymer; titanium dioxide; iron oxide red; potable water; gelatin - treatment of major depression, including prevention of relapse and recurrence where appropriate; generalised anxiety disorder; social anxiety disorder; and panic disorder, including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - venlafaxine hydrochloride, quantity: 169.71 mg - capsule, modified release - excipient ingredients: magnesium stearate; hypromellose; ammonio methacrylate copolymer; sodium lauryl sulfate; basic butylated methacrylate copolymer; titanium dioxide; indigo carmine; erythrosine; potable water; gelatin - treatment of major depression, including prevention of relapse and recurrence where appropriate; generalised anxiety disorder; social anxiety disorder; and panic disorder, including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - desvenlafaxine benzoate, quantity: 146.32 mg (equivalent: desvenlafaxine, qty 100 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; sunset yellow fcf aluminium lake; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - desvenlafaxine benzoate, quantity: 73.16 mg (equivalent: desvenlafaxine, qty 50 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.